4WDT
17beta-HSD5 in complex with 2-nitro-5-(phenylsulfonyl)phenol
Summary for 4WDT
| Entry DOI | 10.2210/pdb4wdt/pdb |
| Related | 4WDS 4WDU 4WDV 4WDW 4WDX |
| Descriptor | Aldo-keto reductase family 1 member C3, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 2-nitro-5-(phenylsulfonyl)phenol, ... (4 entities in total) |
| Functional Keywords | aldo-keto reductase inhibitor, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 38990.03 |
| Authors | Amano, Y.,Yamaguchi, T. (deposition date: 2014-09-09, release date: 2015-04-15, Last modification date: 2024-06-26) |
| Primary citation | Amano, Y.,Yamaguchi, T.,Niimi, T.,Sakashita, H. Structures of complexes of type 5 17 beta-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding. Acta Crystallogr.,Sect.D, 71:918-927, 2015 Cited by PubMed Abstract: Type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5) is an aldo-keto reductase expressed in the human prostate which catalyzes the conversion of androstenedione to testosterone. Testosterone is converted to 5α-dihydrotestosterone, which is present at high concentrations in patients with castration-resistant prostate cancer (CRPC). Inhibition of 17β-HSD5 is therefore considered to be a promising therapy for treating CRPC. In the present study, crystal structures of complexes of 17β-HSD5 with structurally diverse inhibitors derived from high-throughput screening were determined. In the structures of the complexes, various functional groups, including amide, nitro, pyrazole and hydroxyl groups, form hydrogen bonds to the catalytic residues His117 and Tyr55. In addition, major conformational changes of 17β-HSD5 were observed following the binding of the structurally diverse inhibitors. These results demonstrate interactions between 17β-HSD5 and inhibitors at the atomic level and enable structure-based drug design for anti-CRPC therapy. PubMed: 25849402DOI: 10.1107/S1399004715002175 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.5 Å) |
Structure validation
Download full validation report
